SCHEMBL30692457

SCHEMBL30692457

COc1c(Cl)nc(CC(C)C)nc1N1CCOCC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 2/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.41
▸ LMNA P02545 4/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ MAPT P10636 3/20 0.40
▸ HTT P42858 2/20 0.40
▸ NTSR1 P30989 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.39
▸ HPGD P15428 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ CYP2C19 P33261 2/20 0.36
▸ TRPM8 Q7Z2W7 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26647453 0.82 MTOR (0.46) MTORSMN1; SMN2LMNAKMT2AMAPT
SCHEMBL30068010 0.81 MTOR (0.45) MTORSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL26770859 0.81 MTOR (0.43) MTORSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL26647274 0.81 MTOR (0.45) MTORSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL26647309 0.80 MTOR (0.46) MTORSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL30068164 0.80 MTOR (0.46) MTORSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL12463160 0.79 SMN1; SMN2 (0.58) MTORSMN1; SMN2KMT2AMAPTALDH1A1
SCHEMBL26646952 0.79 MTOR (0.51) MTORSMN1; SMN2LMNAMAPTALDH1A1
SCHEMBL30828952 0.77 MTOR (0.48) MTORSMN1; SMN2LMNAKMT2AMAPT
SCHEMBL26646985 0.77 MTOR (0.48) MTORSMN1; SMN2LMNAKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11858915-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 MTOR 519/4885SMN1; SMN2 2786/4885LMNA 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback